EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives

Juan David Marquez-Meneses, Santiago Arturo Olaya-Bonilla, Samuel Barrera-Carreño, Lucía Catalina Tibaduiza-Arévalo iD, Sara Forero-Cárdenas, Liliana Carrillo-Vaca, Luis Carlos Rojas-Rodríguez iD, Carlos Alberto Calderon-Ospina iD, Jesús Rodríguez-Quintana iD

International Journal of Molecular Sciences · 01.06.2025 · 26 (11) · 5338

DOI: 10.3390/ijms26115338 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.06.2025. Verfasst von Juan David Marquez-Meneses und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia. Hauptthemen laut MEDLINE: Substance-Related Disorders, Glucagon-Like Peptide 1, Behavior, Addictive. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundacion CardioInfantil IC and Universidad del Rosario.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of metabolic disorders, have recently emerged as promising candidates for the management of substance use disorders. This review synthesizes preclinical, clinical, and translational evidence on the effects of glucagon-like peptide-1 receptor agonists across addiction models involving alcohol, nicotine, psychostimulants, and opioids. In animal studies, glucagon-like peptide-1 receptor agonists consistently reduce drug intake, attenuate dopamine release in reward circuits, and decrease relapse-like behavior. Clinical and observational studies provide preliminary support for these findings, particularly among individuals with comorbid obesity or insulin resistance. However, several translational barriers remain, including limited blood–brain barrier penetration, species differences in pharmacokinetics, and variability in treatment response due to genetic and metabolic factors. Ethical considerations and methodological heterogeneity further complicate clinical translation. Future directions include the development of central nervous system penetrant analogues, personalized medicine approaches incorporating pharmacogenomics, and rigorously designed trials in diverse populations. Glucagon-like peptide-1 receptor agonists may offer a novel therapeutic strategy that addresses both metabolic and neuropsychiatric dimensions of addiction, warranting further investigation to define their role in the evolving landscape of substance use disorder treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance-Related DisordersGlucagon-Like Peptide 1Behavior, AddictiveHumansAnimalsGlucagon-Like Peptide-1 Receptor AgonistsTranslational Research, BiomedicalGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

alcoholismamphetamine-related disordersbiomedicalblood–brain barrierbrain–gut axiscocaine-related disordersglucagon-like peptide-1 receptor agonistsopioid-related disorderssubstance-related disorderstobacco use disordertranslational research

Substanzen

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.
  • Research Group in Applied Biomedical Sciences (UR Biomed), School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.
  • ZONAMEDICA MR S.A.S., Av Kra. 45 No 105-21, Bogota 110111, Colombia.
  • Fundacion CardioInfantil-Instituto de Cardiología, Bogota 111156, Colombia.
  • Hospital Universitario Mayor Mederi, Bogota 111411, Colombia.

ORCID-Profile: Lucía Catalina Tibaduiza-Arévalo, Luis Carlos Rojas-Rodríguez, Carlos Alberto Calderon-Ospina, Jesús Rodríguez-Quintana

Förderung

  • Fundacion CardioInfantil IC and Universidad del Rosario

Zitieren

APA

Marquez-Meneses, J. D., Olaya-Bonilla, S. A., Barrera-Carreño, S., Tibaduiza-Arévalo, L. C., Forero-Cárdenas, S., Carrillo-Vaca, L., Rojas-Rodríguez, L. C., Calderon-Ospina, C. A., & Rodríguez-Quintana, J. (2025). GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives. International Journal of Molecular Sciences, 26(11), 5338. https://doi.org/10.3390/ijms26115338

Vancouver

Marquez-Meneses JD, Olaya-Bonilla SA, Barrera-Carreño S, Tibaduiza-Arévalo LC, Forero-Cárdenas S, Carrillo-Vaca L, et al. GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives. International Journal of Molecular Sciences. 2025;26(11):5338. doi:10.3390/ijms26115338

BibTeX
@article{MarquezMeneses2025,
  author = {Marquez-Meneses, Juan David and Olaya-Bonilla, Santiago Arturo and Barrera-Carreño, Samuel and Tibaduiza-Arévalo, Lucía Catalina and Forero-Cárdenas, Sara and Carrillo-Vaca, Liliana and Rojas-Rodríguez, Luis Carlos and Calderon-Ospina, Carlos Alberto and Rodríguez-Quintana, Jesús},
  title = {GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {11},
  pages = {5338},
  doi = {10.3390/ijms26115338}
}
Kostenlos starten →